Amgen cancer vaccine due for FDA decision by Oct. 27; GAVI pledges top $7.5B;

> After a three-month delay in its FDA review, Amgen ($AMGN) is expecting a regulatory decision on its cancer vaccine, T-Vec, by Oct. 27. Release

> The GAVI Pledging Conference in Berlin saw new pledges totaling $7.54 billion. Report

> GlaxoSmithKline's ($GSK) Ebola vaccine is safe and generates an immune response, researchers have found. Report

> Three different recombinant protective antigen vaccines formulated with Immunovaccine's DepoVax tech protected animals against a lethal anthrax challenge after one vaccination. Release

> The OTC biotech Vaccinogen says it's closed a previously reported deal for $10 million to study its therapeutic cancer vaccine OncoVax. Release

> A unit of China's Hualan Biological has received government approval to run clinical trials of its H7N9 vaccine. Report

> Tau-based vaccines could transform early Alzheimer's disease treatment, according to GlobalData. Release

And Finally... "Customized soap bubbles" could transform vaccine delivery. More

 

 

Suggested Articles

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.

Since the FDA released new COVID-19 vaccine guidance, HHS Secretary Alex Azar has discussed firing FDA Commissioner Stephen Hahn, Politico reports.